Genomic and signalling pathway characterization of the NZM panel of melanoma cell lines: A valuable model for studying the impact of genetic diversity in melanoma. (4th July 2020)

• Record Type: Journal Article
• Authors: Tran, Khanh B.; Gimenez, Gregory; Tsai, Peter; Kolekar, Sharada; Rodger, Euan J.; Chatterjee, Aniruddha; Jabed, Anower; Shih, Jen‐Hsing; Joseph, Wayne R.; Marshall, Elaine S.; Wang, Qian; Print, Cristin G.; Eccles, Michael R.; Baguley, Bruce C.; Shepherd, Peter R.
• Is Part Of: Pigment cell & melanoma research. Volume 34:Number 1(2021)
• Page Start: 136
• Page End: 143
• Publication Date: 2020-07-04
• Subjects: BRAF -- cancer -- CTTNB1 -- immunotherapy -- KRAS -- melanoma -- molecular subtypes -- neoantigen -- NF1 -- NRAS -- PDGFRA -- PIK3CA -- testis antigen; Melanoma -- Periodicals; Chromatophores -- Periodicals; Animal pigments -- Periodicals; 616.99477
• DOI: 10.1111/pcmr.12908
• Languages: English
• ISSNs: 1755-1471

Abstract

Abstract: Melanoma is a disease associated with a very high mutation burden and thus the possibility of a diverse range of oncogenic mechanisms that allow it to evade therapeutic interventions and the immune system. Here, we describe the characterization of a panel of 102 cell lines from metastatic melanomas (the NZM lines), including using whole‐exome and RNA sequencing to analyse genetic variants and gene expression changes in a subset of this panel. Lines possessing all major melanoma genotypes were identified, and hierarchical clustering of gene expression profiles revealed four broad subgroups of cell lines. Immunogenotyping identified a range of HLA haplotypes as well as expression of neoantigens and cancer–testis antigens in the lines. Together, these characteristics make the NZM panel a valuable resource for cell‐based, immunological and xenograft studies to better understand the diversity of melanoma biology and the responses of melanoma to therapeutic interventions.